EMA Doubles Number Of EU Early Access Approval Recommendations
13 CHMP Positive Opinions Were For Conditional Marketing Authorization
Executive Summary
The EU’s special provisions for speeding new products towards approval proved more popular than ever with drug sponsors last year.